Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coupang Inc (CPNG) vs 10X Genomics Inc (TXG) Price & Performance

Coupang IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Coupang Inc vs 10X Genomics Inc — how do they compare? Coupang Inc trades at $16.4 (market cap $29.34B), while 10X Genomics Inc trades at $57.64 (market cap $7.52B). The key difference: Coupang Inc is far larger — about 3.9× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.

CPNGTXG
Market Cap
$29.34B$7.52B
Sector
Consumer CyclicalHealth
52-Week High
$33.53$58.57
52-Week Low
$15.12$11.34
Enterprise Value
$28.86B$7.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coupang Inc

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.

10X Genomics Inc

TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.

Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG